USD 0.52
(-1.52%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 94.51 Million USD | 30.73% |
2022 | 72.3 Million USD | 28.26% |
2021 | 56.37 Million USD | -29.45% |
2020 | 79.9 Million USD | -70.42% |
2019 | 270.17 Million USD | 13.95% |
2018 | 237.08 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q3 | 74.88 Million USD | -5.9% |
2024 Q2 | 79.58 Million USD | -14.15% |
2024 Q1 | 92.7 Million USD | -1.92% |
2023 Q3 | 88.23 Million USD | 4.27% |
2023 FY | 94.51 Million USD | 30.73% |
2023 Q4 | 94.51 Million USD | 7.12% |
2023 Q2 | 84.61 Million USD | 10.98% |
2023 Q1 | 76.24 Million USD | 5.45% |
2022 Q2 | 67.55 Million USD | 25.41% |
2022 Q1 | 53.87 Million USD | -4.43% |
2022 FY | 72.3 Million USD | 28.26% |
2022 Q4 | 72.3 Million USD | 9.38% |
2022 Q3 | 66.1 Million USD | -2.16% |
2021 Q1 | 79.05 Million USD | -1.06% |
2021 FY | 56.37 Million USD | -29.45% |
2021 Q4 | 56.37 Million USD | -23.79% |
2021 Q3 | 73.96 Million USD | -2.72% |
2021 Q2 | 76.03 Million USD | -3.82% |
2020 Q2 | 66.36 Million USD | 0.0% |
2020 Q4 | 79.9 Million USD | -73.52% |
2020 Q3 | 301.72 Million USD | 354.61% |
2020 FY | 79.9 Million USD | -70.42% |
2020 Q1 | - USD | -100.0% |
2019 FY | 270.17 Million USD | 13.95% |
2019 Q4 | 270.17 Million USD | 0.0% |
2019 Q1 | - USD | 0.0% |
2018 FY | 237.08 Million USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Aclaris Therapeutics, Inc. | 40.22 Million USD | -134.962% |
Applied DNA Sciences, Inc. | 8.77 Million USD | -976.594% |
Aspira Women's Health Inc. | 8.62 Million USD | -995.584% |
BioNexus Gene Lab Corp. | 1.74 Million USD | -5325.901% |
bioAffinity Technologies, Inc. | 3.36 Million USD | -2707.714% |
bioAffinity Technologies, Inc. | 3.36 Million USD | -2707.714% |
Bionano Genomics, Inc. | 118.24 Million USD | 20.069% |
CareDx, Inc | 223.28 Million USD | 57.671% |
Check-Cap Ltd. | 1.33 Million USD | -7006.466% |
Castle Biosciences, Inc. | 86.54 Million USD | -9.214% |
DarioHealth Corp. | 38.24 Million USD | -147.133% |
Exact Sciences Corporation | 3.32 Billion USD | 97.158% |
Fulgent Genetics, Inc. | 139.82 Million USD | 32.403% |
Guardant Health, Inc. | 1.62 Billion USD | 94.193% |
ICON Public Limited Company | 7.74 Billion USD | 98.78% |
IDEXX Laboratories, Inc. | 1.77 Billion USD | 94.676% |
Illumina, Inc. | 4.36 Billion USD | 97.835% |
Intelligent Bio Solutions Inc. | 5.59 Million USD | -1589.091% |
iSpecimen Inc. | 6.07 Million USD | -1455.036% |
Standard BioTools Inc. | 159.86 Million USD | 40.878% |
MDxHealth SA | 121.92 Million USD | 22.48% |
23andMe Holding Co. | 206.64 Million USD | 54.262% |
Medpace Holdings, Inc. | 1.09 Billion USD | 91.391% |
Myriad Genetics, Inc. | 312.9 Million USD | 69.794% |
Mainz Biomed B.V. | 12.15 Million USD | -677.282% |
ENDRA Life Sciences Inc. | 1.09 Million USD | -8530.361% |
NeoGenomics, Inc. | 739.69 Million USD | 87.222% |
Neogen Corporation | 1.44 Billion USD | 93.436% |
Inotiv, Inc. | 588.04 Million USD | 83.927% |
Natera, Inc. | 691.79 Million USD | 86.338% |
OPKO Health, Inc. | 622.47 Million USD | 84.816% |
Psychemedics Corporation | 6.59 Million USD | -1332.495% |
Prenetics Global Limited | 44.01 Million USD | -114.744% |
Prenetics Global Limited | 44.01 Million USD | -114.744% |
Precipio, Inc. | 3.67 Million USD | -2473.965% |
Personalis, Inc. | 95.65 Million USD | 1.194% |
RadNet, Inc. | 2.07 Billion USD | 95.441% |
Sera Prognostics, Inc. | 25.28 Million USD | -273.832% |
Sotera Health Company | 2.68 Billion USD | 96.482% |
Neuronetics, Inc. | 81.64 Million USD | -15.77% |
Star Equity Holdings, Inc. | 21.67 Million USD | -336.06% |
Star Equity Holdings, Inc. | 21.67 Million USD | -336.06% |
Trinity Biotech plc | 83.38 Million USD | -13.35% |
Twist Bioscience Corporation | 152.97 Million USD | 38.213% |
Exagen Inc. | 34.25 Million USD | -175.959% |